GHK-Cu: The Copper Tripeptide Research Guide

GHK-Cu is the copper-bound form of the human tripeptide Glycyl-L-Histidyl-L-Lysine (GHK). It occurs naturally in human plasma, saliva, and urine, and its concentration declines with age — from roughly 200 ng/mL at age 20 to under 80 ng/mL by age 60. That decline is one of the reasons GHK-Cu became a focal point in tissue-aging research.

What GHK-Cu actually does

When GHK binds a single copper(II) ion it forms a stable complex that acts as a signaling molecule rather than a structural protein. The complex is taken up by fibroblasts and keratinocytes and changes gene expression across thousands of transcripts.

In published genomic research, GHK-Cu has been shown to:

• Up-regulate genes associated with skin repair, collagen synthesis, and elastin production
• Down-regulate inflammatory cytokines and TGF-β1 (a fibrosis driver)
• Reset the gene-expression pattern of damaged cells toward a younger phenotype
• Modulate antioxidant defense via Nrf2 signaling

This is why GHK-Cu shows up across three different research domains at once: dermatology, hair-follicle biology, and connective-tissue repair.

Research findings: skin

GHK-Cu is the most cited peptide in topical skin-aging research. Studies report:

• Increased dermal collagen and elastin density
• Improved skin firmness and reduced photodamage markers
• Better wound-edge closure rates in animal models
• Reduced fine-line depth in human cosmetic trials at low topical concentrations (0.1–0.5%)

Research findings: hair

In vitro studies on dermal papilla cells show GHK-Cu extending the anagen (growth) phase of the follicle cycle and increasing VEGF expression, which improves peri-follicular vascularization. Research on alopecia models reports thicker shaft diameter and longer anagen retention.

Research findings: connective tissue and wound repair

GHK-Cu is widely studied alongside BPC-157 and TB-500 in soft-tissue protocols. Published work describes:

• Accelerated granulation tissue formation
• Improved tensile strength of healing wounds
• Up-regulation of decorin (a key proteoglycan in tendon healing)

Common research dose ranges

For injectable subcutaneous research applications, reported ranges typically fall between 1 mg and 3 mg per dose, administered 2–5 times per week. Some long-arc protocols use lower daily doses (0.5–1 mg) over 8–12 weeks.

Topical research formulations typically use 0.05–1% by mass in a base cream or serum.

Dose figures above are reference figures observed in published peptide research literature. They are not medical advice or recommendations for human use.

Reconstitution from a 50 mg vial

GHK-Cu ships lyophilized and is reconstituted with bacteriostatic water. A typical reconstitution from a 50 mg vial:

BAC water	Concentration	2 mg dose volume	U-100 units
2 mL	25 mg/mL	0.08 mL	8 units
3 mL	16.67 mg/mL	0.12 mL	12 units
5 mL	10 mg/mL	0.20 mL	20 units

Reconstituted GHK-Cu is light-sensitive and stored refrigerated at 2–8 °C. Research references describe stability windows of 4–6 weeks under cold, dark storage. The solution has a characteristic blue tint from the copper complex — this is normal.

Stacking notes

GHK-Cu pairs naturally with BPC-157 and TB-500 in tissue-repair research protocols. Each peptide hits a different lever:

• BPC-157 → cytoprotection and angiogenesis
• TB-500 → actin remodelling and cell migration
• GHK-Cu → gene-expression reset and collagen scaffolding

Use the ZORVYN Dose Calculator to verify your reconstitution math before any research handling.